Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 1 to 25 from a total of 87
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
ADVATE |
Takeda Manufacturing Austria AG |
EU/1/03/271 | 02.03.2004 | |
Prothromplex NF 500 |
Takeda GmbH |
PEI.H.11717.02.1 | 21.04.2023 | |
Prothromplex NF 600 |
Takeda GmbH |
PEI.H.11717.01.1 | 13.08.2014 | |
IMMUNINE 1200 I.E. |
Takeda GmbH |
PEI.H.03595.03.1 | 05.05.2008 | |
IMMUNINE 600 I.E. |
Takeda GmbH |
PEI.H.03595.02.1 | 05.05.2008 | |
|
IMMUNATE 500 I.E. |
Takeda GmbH |
3854.02.00 | 20.10.1983 | |
|
IMMUNATE 1000 I.E. |
Takeda GmbH |
3854.03.00 | 20.10.1983 | |
|
Immuseven |
Takeda GmbH |
PEI.H.03341.01.1 | 28.11.2005 | |
Recombinate Antihaemophilie Faktor (rekombinant) 1000 |
Takeda GmbH |
28530.02.00 | 30.07.1993 | |
Altuvoct |
Swedish Orphan Biovitrum AB, Schweden |
EU/1/24/1824 | 17.06.2024 | |
|
Alprolix |
Swedish Orphan Biovitrum AB (publ) |
EU/1/16/1098 | 12.05.2016 | |
|
Elocta |
Swedish Orphan Biovitrum AB (publ) |
EU/1/15/1046 | 19.11.2015 | |
Cofact 500 |
Prothya Biosolutions Netherlands B.V. |
PEI.H.03453.02.1 | 31.08.2007 | |
BeneFIX |
Pfizer Europe MA EEIG |
EU/1/97/047 | 27.08.1997 | |
ReFacto AF |
Pfizer Europe MA EEIG |
EU/1/99/103 | 13.04.1999 | |
Octanate 1000 |
Orifarm GmbH |
PEI.H.12088.01.1 | 24.03.2021 | |
|
OCTANINE F 500 |
OCTAPHARMA GmbH |
10501a/97-2 | 07.09.2000 | |
|
Octanate 500 |
OCTAPHARMA GmbH |
10500a/97-2 | 04.08.1998 | |
|
Wilate 450 |
OCTAPHARMA GmbH |
PEI.H.01918.01.1 | 08.02.2005 | |
|
Octanate 250 |
OCTAPHARMA GmbH |
10500a/97-1 | 04.08.1998 | |
|
Wilate 500 |
OCTAPHARMA GmbH |
PEI.H.01918.03.1 | 22.12.2011 | |
|
Wilate 900 |
OCTAPHARMA GmbH |
PEI.H.01918.02.1 | 08.02.2005 | |
|
OCTANINE F 1000 |
OCTAPHARMA GmbH |
10501a/97-3 | 07.09.2000 | |
|
Octaplex 1000 |
OCTAPHARMA GmbH |
PEI.H.02312.02.1 | 11.08.2015 | |
|
Octanate 1000 |
OCTAPHARMA GmbH |
10500a/97-3 | 04.08.1998 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 17.06.2025
